Skip to main content
SpringerLink
Log in

The Detection of Heterozygous Familial Hypercholesterolemia in Ireland

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant condition with a population prevalence of 1 in 500, and is associated with significant cardiovascular morbidity and mortality. It may be caused by mutations in the low-density lipoprotein (LDL) receptor, apolipoprotein B100 (Apo B100), or proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, with over 1,000 causative mutations described. Statin therapy in HeFH is considered effective and safe. Audit data suggest that approximately 80% of the putative HeFH population remains unidentified and, therefore, there is a need to develop a strategy for the identification of affected individuals so that early lipid-lowering treatment may be offered. There is good evidence showing the effectiveness and acceptability of HeFH screening programs in Europe. The authors describe a protocol for an all island approach to HeFH detection in the Republic of Ireland/Northern Ireland. Index cases will be identified by opportunistic screening using the Simon Broome, or Make Early Diagnosis to Prevent Early Death (MedPed) and World Health Organization (WHO) criteria. Patients identified as “definite,” “probable,” or “possible” HeFH criteria will be offered genetic testing. The authors expect causative mutations to be identified in approximately 80% of patients with “definite” HeFH but in only approximately 20% of patients with “possible” HeFH. Cascade screening will be undertaken in first-degree relatives of the index case using genetic testing (where a causative mutation has been identified), or otherwise using LDL cholesterol concentration. The establishment of a HeFH screening program on an all-island basis will require: expansion of the existing molecular genetics diagnostic services, the establishment of a cohort of nurses/genetic counselors, a HeFH database to support cascade testing, the development of a network of lipid clinics (in a primary or secondary care setting), and an educational initiative to raise awareness of HeFH among healthcare professionals and the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Northern Ireland Statistics and Research Agency. Registrar General Annual Report 2009. Belfast 2010. Available at: http://www.nisra.gov.uk/publications/archive/NISRA_Annual_Report_20089.pdf. Accessed Jan 5 2012.

  2. Ireland and Northern Ireland Public Health Observatory (INIsPHO). Preliminary estimates and forecasts of the population prevalence of selfreported hypertension, ischaemic heart disease and stroke in the Republic of Ireland from 2005–2015. Available at: www.publichealth.ie. Accessed Jul 11 2011.

  3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. In: Scriver CR, Sly WS, Childs B, et al., eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Companies; 2001:2863–2894.

    Google Scholar 

  4. NICE. Identification and management of familial hypercholesterolaemia. NICE Clinical Guideline 71. Available at: www.nice.org.uk/CG071. Accessed Jan 6 2012.

  5. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43:943–949.

    Article  PubMed  CAS  Google Scholar 

  6. O’Neill FH, Patel DD, Knight BL, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol. 2001;21:832–837.

    Article  PubMed  Google Scholar 

  7. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1–14.

    Article  PubMed  CAS  Google Scholar 

  8. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;302:893–896.

    Google Scholar 

  9. World Health Organization. Familial hypercholesterolaemia [FH]: Report of a second WHO consultation. Geneva: World Health Organization. 1999. Available at: www.who.int/entity/genomics/publications/reports/en/. Accessed Dec 21 2012.

  10. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolaemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171–176.

    Article  PubMed  CAS  Google Scholar 

  11. European Association for Cardiovascular Prevention and Rehabilitation; Reiner Z, Catapano AL, De Backer G. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology [ESC] and the European Atherosclerosis Society [EAS]. Eur Heart J. 2011;32:1769–1818.

    Article  PubMed  Google Scholar 

  12. Koivunen-Niemel J. Sonography of the Achilles tendon in hypercholesterolaemia. J Intern Med. 1993;234:401–405.

    Article  Google Scholar 

  13. Graham CA, McIlhatton BP, Kirk CW, et al. Genetic screening protocol for familial hypercholesterolaemia which includes spicing defects gives an improved mutation rate detection rate. Atherosclerosis. 2005;182:331–340.

    Article  PubMed  CAS  Google Scholar 

  14. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolaemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–420.

    Article  PubMed  Google Scholar 

  15. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolaemia in a Danish population. Atherosclerosis. 2005;180:155–160.

    Article  PubMed  CAS  Google Scholar 

  16. Wilson JMG, Jungner G. Principles and practice for the screening of disease. WHO Chronicle. 1968;22:473.

    Google Scholar 

  17. Gray J, Jaiyeola A, Whiting M, et al. Identifying patient with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart. 2008;94:754–758.

    Article  PubMed  CAS  Google Scholar 

  18. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade screening. Clin Chem Lab Med. 2008;46:791–803.

    Article  PubMed  CAS  Google Scholar 

  19. Defesche JC, Lansberg Pj, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolaemia. Semin Vasc Med. 2004;4:59–65.

    Article  PubMed  Google Scholar 

  20. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165–168.

    Article  PubMed  CAS  Google Scholar 

  21. Marks D, Thorogood M, Neill SM, Humphries SE, Neil HA. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen. 2006;13:156–159.

    Article  PubMed  CAS  Google Scholar 

  22. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ. 2000;321:1497–1500.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Chemistry Laboratory, Altnagelvin Hospital, Londonderry, Northern Ireland

    Maurice J. O’Kane

  2. Craigavon Cardiac Centre, Southern Health and Social Care Trust, Craigavon, Northern Ireland

    Ian B. Menown

  3. Charlemont Cardiology, Charlemont Clinic, Charlemont Mall, Dublin 2, Ireland

    Ian Graham

  4. Division of Cardiology, Department of Medicine, The Adelaide and Meath Hospital, Trinity College Dublin, Tallaght, Ireland

    Vincent Maher

  5. Diabetes Institute of Ireland, Beacon Hospital Dublin 18 and Trinity College Dublin, Dublin 2, Ireland

    Gerald Tomkin

  6. Lipid Clinic, Royal Victoria Hospital, Belfast, Northern Ireland

    Paul Nicholls

  7. Regional Medical Genetics Laboratory, Belfast City Hospital, Belfast, Northern Ireland

    Colin Graham

Authors
  1. Maurice J. O’Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian B. Menown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent Maher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerald Tomkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul Nicholls
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Colin Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurice J. O’Kane.

Additional information

On behalf of the Irish Atherosclerosis Society

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Kane, M.J., Menown, I.B., Graham, I. et al. The Detection of Heterozygous Familial Hypercholesterolemia in Ireland. Adv Therapy 29, 456–463 (2012). https://doi.org/10.1007/s12325-012-0021-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0021-0

Keywords

Search

Navigation